1. Home
  2. RGEN vs CHE Comparison

RGEN vs CHE Comparison

Compare RGEN & CHE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGEN
  • CHE
  • Stock Information
  • Founded
  • RGEN 1981
  • CHE 1970
  • Country
  • RGEN United States
  • CHE United States
  • Employees
  • RGEN N/A
  • CHE N/A
  • Industry
  • RGEN Medical/Dental Instruments
  • CHE Medical/Nursing Services
  • Sector
  • RGEN Health Care
  • CHE Health Care
  • Exchange
  • RGEN Nasdaq
  • CHE Nasdaq
  • Market Cap
  • RGEN 7.6B
  • CHE 8.0B
  • IPO Year
  • RGEN N/A
  • CHE N/A
  • Fundamental
  • Price
  • RGEN $156.55
  • CHE $533.96
  • Analyst Decision
  • RGEN Buy
  • CHE Buy
  • Analyst Count
  • RGEN 12
  • CHE 2
  • Target Price
  • RGEN $187.44
  • CHE $641.50
  • AVG Volume (30 Days)
  • RGEN 470.1K
  • CHE 100.0K
  • Earning Date
  • RGEN 02-19-2025
  • CHE 02-25-2025
  • Dividend Yield
  • RGEN N/A
  • CHE 0.34%
  • EPS Growth
  • RGEN N/A
  • CHE 22.57
  • EPS
  • RGEN N/A
  • CHE 19.78
  • Revenue
  • RGEN $633,513,000.00
  • CHE $2,377,206,000.00
  • Revenue This Year
  • RGEN $2.28
  • CHE $8.28
  • Revenue Next Year
  • RGEN $9.88
  • CHE $7.06
  • P/E Ratio
  • RGEN N/A
  • CHE $26.99
  • Revenue Growth
  • RGEN N/A
  • CHE 6.83
  • 52 Week Low
  • RGEN $113.50
  • CHE $512.12
  • 52 Week High
  • RGEN $211.13
  • CHE $654.62
  • Technical
  • Relative Strength Index (RSI)
  • RGEN 60.07
  • CHE 48.79
  • Support Level
  • RGEN $149.15
  • CHE $520.16
  • Resistance Level
  • RGEN $160.64
  • CHE $535.09
  • Average True Range (ATR)
  • RGEN 5.96
  • CHE 9.17
  • MACD
  • RGEN 0.91
  • CHE 1.99
  • Stochastic Oscillator
  • RGEN 79.57
  • CHE 83.42

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 54% of 2023 revenue, while chromatography, proteins, and process analytics were 20%, 16%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

About CHE Chemed Corp

Chemed Corp operates subsidiaries in two main segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue. It provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The vast majority of the segment's revenue is received from the Medicare and Medicaid reimbursement programs. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers. Chemed generates the majority of its revenue from business in the United States.

Share on Social Networks: